Crystal Ball Health Policies: A Case Against Preventive Testing For Alzheimer's Disease

Area of Science:

• Neuroscience
• Gerontology
• Pharmacology

Background:

• A new Alzheimer's disease (AD) drug, the first in nearly two decades, has been approved, prompting discussions on preclinical diagnosis and symptom management.
• Current AD medications are acknowledged by the scientific community to only slow disease progression, not halt or reverse it.
• The advent of potential early-stage AD drugs may increase interest in biomarker research and predictive testing, even for healthy individuals.

Purpose of the Study:

• To evaluate the implications of widespread preclinical diagnosis and predictive testing for Alzheimer's disease.
• To caution against the premature and extensive use of predictive testing in the absence of truly effective treatments.

Main Methods:

• The study presents a critical analysis of the potential societal and individual consequences of extensive biomarker use for Alzheimer's prediction.
• Illustrative examples are provided to demonstrate the risks associated with early prediction testing.

Main Results:

• Widespread use of predictive biomarkers for Alzheimer's disease could negatively impact individuals and society.
• The current therapeutic landscape does not support the broad application of preclinical diagnostic tests.

Conclusions:

• Access to predictive testing for Alzheimer's disease should be restricted until genuinely effective treatments become available.
• A cautious approach is warranted to prevent potential harm from early diagnosis without adequate therapeutic options.